Short Interest in BioNTech SE (NASDAQ:BNTX) Expands By 29.6%

BioNTech SE (NASDAQ:BNTX - Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 2,410,000 shares, a growth of 29.6% from the September 30th total of 1,860,000 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily volume of 975,500 shares, the days-to-cover ratio is currently 2.5 days.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently modified their holdings of BNTX. Covestor Ltd grew its position in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company's stock valued at $38,000 after buying an additional 133 shares during the last quarter. GAMMA Investing LLC grew its position in shares of BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company's stock valued at $41,000 after buying an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock worth $43,000 after purchasing an additional 252 shares during the last quarter. Blue Trust Inc. grew its position in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock worth $55,000 after purchasing an additional 388 shares during the last quarter. Finally, Crewe Advisors LLC bought a new position in BioNTech in the 1st quarter worth about $75,000. Institutional investors own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

BNTX has been the topic of several research reports. Morgan Stanley upgraded shares of BioNTech from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $93.00 to $145.00 in a research report on Tuesday, September 24th. JPMorgan Chase & Co. upgraded shares of BioNTech from an "underweight" rating to a "neutral" rating and raised their target price for the stock from $91.00 to $125.00 in a research report on Monday, September 16th. Hsbc Global Res upgraded shares of BioNTech from a "hold" rating to a "strong-buy" rating in a report on Friday, August 2nd. UBS Group lifted their price target on shares of BioNTech from $97.00 to $131.00 and gave the company a "neutral" rating in a report on Wednesday, September 18th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of BioNTech from $95.00 to $150.00 and gave the company a "buy" rating in a report on Thursday, September 19th. Five analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $135.54.

BioNTech Stock Up 2.5 %

BNTX stock traded up $2.78 during mid-day trading on Monday, hitting $113.26. 666,760 shares of the company were exchanged, compared to its average volume of 782,553. The company has a market capitalization of $26.92 billion, a PE ratio of 226.52 and a beta of 0.24. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The firm has a fifty day simple moving average of $107.73 and a 200 day simple moving average of $95.16.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The company had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. BioNTech's revenue was down 23.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.86) earnings per share. On average, research analysts forecast that BioNTech will post -3.04 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.